http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2735978-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa45e723acac586815d7c2524dea6bdd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate | 2011-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7da72849a79394bf1a88d550db0b17db |
| publicationDate | 2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2735978-T3 |
| titleOfInvention | Medical liquid, treatment procedure and liquid use |
| abstract | Use of a medical liquid for the evaluation and / or preservation of an organ, tissue or parts thereof, extracted, prior to transplantation, comprising: a NET inhibitor selected from cocaine or a stimulant cocaine analogue, in which the Stimulating cocaine analog is selected from: dimethylcocaine or larocaine (DMC) ((3-diethylamino-2,2-dimethylpropyl) -4-aminobenzoate); and 3- (p-fluorobenzoyl) tropane ((1R, 5S) - (8-methyl-8-azabicyclo [3.2.1] octan-3-yl) -4-fluorobenzoate); b-CIT ((1R, 2S, 3S, 5S) -3- (4-iodophenyl) -8-methyl-8-azabicyclo [3.2.1] methyl octane-2-carboxylate); b-CPPIT (3b- (4'-chlorophenyl) -2b- (3'-phenylisoxazol-5'-yl) tropane); FE-b-CPPIT (N- (2'-fluoroethyl) -3b- (4'-chlorophenyl) -2b- (3'-phenylisoxazol-5'-yl) nortropane); FP-b-CPPIT (N- (3'-fluoropropyl) -3b- (4'-chlorophenyl) -2b- (3'-phenylisoxazol-5'-yl) nortropane); Altropane ((1R, 2S, 3S, 5S) -3- (4- fluorophenyl) -8 - [(E) -3-iodoprop-2-enyl] -8-azabicyclo [3.2.1] octane-2-carboxylate methyl); Brasofensine ((E) -1- [(1R, 2R, 3S, 5S) -3- (3,4-dichlorophenyl) -8-methyl-8-azabicyclo [3.2.1] oct-2-yl] -N- methoxymethanimine); CFT ((1R, 2S, 3S, 5S) -3- (4-fluorophenyl) -8-methyl-8-azabicyclo [3.2.1] methyl octane-2-carboxylate); Dichloropane ((1R, 2S, 3S, 5S) -3- (3,4-dichlorophenyl) -8-azabicyclo [3.2.1] methyl octane-2-carboxylate); Difluoropin ((1S, 2S, 3S, 5R) -3- [bis (4-fluorophenyl) methoxy] -8-methyl-8-azabicyclo [3.2.1] methyl octane-2-carboxylate); Ioflupane (123I) ((1R, 2S, 3S, 5S) -3- (4- iodophenyl) -8- (3-fluoropropyl) -8-azabicyclo [3.2.1] methyl octane-2-carboxylate); Nocaine ((3R, 4S) -4- (4-chlorophenyl) -1-methylpiperidine-3-carboxylate); Tesofensine ((1R, 2R, 3S, 5S) -3- (3,4-dichlorophenyl) -2- (ethoxymethyl) -8-methyl-8-azabicyclo [3.2.1] octane); Troparil ((1R, 2S, 3S, 5S) -8-methyl-3-phenyl-8-azabicyclo [3.2.1] methyl octane-2-carboxylate); Tropoxane ((1R, 2S, 3S, 5S) -3- (3,4-dichlorophenyl) -8-oxabicyclo [3.2.1] methyl octane-2-carboxylate); (-) - methyl-1-methyl-4b- (2-naphthyl) piperidine-3b-carboxylate ((3S, 4S) -1-methyl-4-naphthalen-2-yl-piperidine-3-carboxylate); PIT (2-propanoyl-3- (4-isopropylphenyl) -tropane); PTT (2b-propanoyl-3b- (4-tolyl) -tropane); RTI-121, IPCIT ((1R, 2S, 3S) -3- (4-iodophenyl) -8-methyl-8-azabicyclo [3.2.1] octane-2-carboxylate propan-2-yl); RTI-126 ((1R, 2S, 3S, 5S) -8-methyl-2- (1,2,4-oxadiazol-5- methyl) -3-phenyl-8-azabicyclo [3.2.1] octane); RTI-150 ((1R, 2S, 3S, 5S) -8-methyl-3- (4-methylphenyl) -8-azabicyclo [3.2.1] octane-2-cyclobutyl carboxylate); RTI-336 ((1R, 2S, 3S, 5S) -8-methyl-2- (3- (4-methylphenyl) isoxazol-5-yl) -3- (4-chlorophenyl) -8- azabicyclo [3.2.1 ]octane); or WF-23 (2b-propanoyl-3b- (2-naphthyl) -tropane); WF-33 (2a- (propanoyl) -3b- (2- (6-methoxynaphthyl)) - tropane); adrenaline and norepinephrine; an oncotic agent, wherein said oncotic agent is albumin or dextran or a combination thereof; hormones, in which said hormones are any of thyroxine; triiodothyronine; or cortisone or a combination thereof; and electrolytes and, optionally, nutrients, in physiological concentrations in a physiologically acceptable medium to maintain vascular tone and reduce the formation of edema in the organ, tissue or parts thereof, removed. |
| priorityDate | 2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 225.